Recent Interviews

Justin Reid, President and CEO, Troilus Gold Corp.

Justin Reid
President and CEO | Troilus Gold Corp.
36 Lombard Street, Floor 4, M5C 2X3 Toronto, Ontario (CAN)

+1 (647) 276-0050

Interview Troilus Gold: "We are convinced that Troilus is more than just a mine".

John Jeffrey, CEO, Saturn Oil + Gas Inc.

John Jeffrey
CEO | Saturn Oil + Gas Inc.
Suite 1000 - 207 9 Ave SW, T2P 1K3 Calgary (CAN)


Saturn Oil + Gas CEO John Jeffrey: "Acquisition has increased production by 2,000%"

Gary Cope, President and CEO, Barsele Minerals

Gary Cope
President and CEO | Barsele Minerals
Suite 1130 - 1055 W. Hastings Street, V6E 2E9 Vancouver (CAN)

+1(604) 687-8566

Interview Barsele Minerals: 'I have never seen a project with such good general conditions'.

24. June 2021 | 12:52 CET

CureVac, Cardiol Therapeutics, Bayer - Where we go from here

  • Biotechnology
Photo credits:

Biotechnology has an extraordinary impact on our lives. The perception and appreciation of the future industry of the 21st century has increased significantly in the past year. All thanks due to the race for vaccines against the coronavirus. Yet investing in a biotechnology startup requires patience and a willingness to take risks. The risk that an active ingredient will not work in the end, as the example of CureVac shows, is high. On the other hand, however, investors have the opportunity to multiply their invested capital in the event of successful approval.

time to read: 3 minutes by Stefan Feulner
ISIN: CUREVAC N.V. O.N. | NL0015436031 , CARDIOL THERAPEUTICS | CA14161Y2006 , BAYER AG NA O.N. | DE000BAY0017



Stefan Feulner

The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.

About the author

Significant blockbuster potential

Since March of last year, Corona has been the dominant topic in our daily lives. In contrast, other, more serious diseases took a back seat. For example, few people are probably aware that cardiovascular disease accounts for about 40% of all deaths in Western countries. Cardiol Therapeutics has set its sights precisely on this billion-dollar market. The Company is focusing on manufacturing pharmaceutical cannabidiol (CBD) products and developing innovative therapies for heart disease, including acute myocarditis and other causes of heart failure. The active ingredient CardiolRx, which can be administered orally as well as subcutaneously to patients, has already passed Phase 1 trials with no side effects. In addition, a significant reduction in existing inflammation and an improvement in endothelial dysfunction was observed.

Now, the critical Phase II/III trial involving 422 high-risk patients hospitalized in conjunction with Covid-19 is about to begin. A total of CAD 22 million was raised from the capital market in a capital increase to fund the cost-intensive research work. The placement was several times oversubscribed and shows the attention Cardiol Therapeutics already enjoys on the capital market. The issue price was CAD 3.60 per share. In addition, the Canadian Company recently filed for listing on the NASDAQ Capital Market.

The share is currently quoted at CAD 3.08. The analysts of GBC Research see Cardiol Therapeutics as a clear buy candidate and assigned a price target of CAD 15.77 in the study published yesterday, which would mean a fivefold increase of the share price. Thus, Cardiol Therapeutics is a leader in therapeutic trials with cannabidiol to exploit the great opportunities in inflammatory heart disease, they said. Experts project substantial cumulative profits of around CAD 3 billion over the next 10 years with an average margin of 85%.

Apples compared to oranges?

The drama is well known. For a long time, vaccine maker CureVac took its time researching its first-generation vaccine, CVnCov, to set itself apart from the faster competition from BioNTech, AstraZeneca and Moderna. The advantages in cooling, longer shelf life or fewer side effects were apparent. Then came the shock at the interim analysis, which showed an efficacy of only 47% against Covid-19 disease "of any severity." Although the Tübingen-based Company plans to continue testing and complete data analysis from the final study phase in the next 3 weeks, efficacy comparable to that of the competition would border on miraculous.

The longer lead time that CureVac needed to be compared to others is now falling on the Company's feet. According to its CEO, Franz-Werner Hass, the vaccine is unfairly criticized. No other vaccine has been tested on so many virus variants, 29 in all. The original virus, the wild type, on the other hand, hardly plays a role anymore. "The figures on the efficacy of the other vaccines would probably look different if their studies had been conducted at a later date."

From a technical perspective, the 40% downturn could be followed by a bottoming out at a low level. The sell-off to USD 47.12 was followed by a brief recovery move to USD 68.36 but was halted by further selling on high volume. Yesterday, the price was trading at USD 58.10, just above the support zone at USD 56.90. If this breaks, the USD 50 mark would be the target. Furthermore, if no positive corporate news hits the ticker in the next few weeks, we believe the all-time low of USD 43.0 marked last year, is also in danger.

Bayer continues

Despite the setback, the pharmaceutical group Bayer intends to continue its cooperation with CureVac and support the Tübingen-based Company regarding logistics and distribution. In addition, the planned construction of a production facility for the CureVac vaccine in Wuppertal is also being pushed ahead. Production is scheduled to start at the end of the year. From 2022, 160 million vaccine doses per year are to be produced there.

By contrast, the Leverkusen-based Company received positive news from Asia. The Japanese Ministry of Health, Labor and Welfare approved the drug Verquvo for the treatment of patients with chronic heart failure. The drug was developed in collaboration with US pharmaceutical giant Merck & Co. Bayer Pharma CEO Stefan Oelrich expects peak annual sales of around EUR 1 billion for the drug, with revenues to be shared between the two partners.

Meanwhile, the glyphosate litigation continues to weigh on Bayer's share price. On Tuesday evening, a hearing was held in the appeal proceedings of one of the three glyphosate lawsuits that Bayer lost. In it, a judge sharply criticized the lawyer for Bayer's side for documents filed in connection with the hearing. As a result, the pharmaceutical giant's stock temporarily fell below the critical support level of EUR 50 but recovered in the course of trading.


Stefan Feulner

The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.

About the author

Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.

Related comments:

27. July 2021 | 13:01 CET | by Stefan Feulner

BioNTech, XPhyto Therapeutics, MorphoSys - Here we go again

  • Biotechnology

The numbers of new SARS-CoV-2 infections in Germany are rising again, albeit still at a relatively low level. Due to the spread of the Delta variant, Health Minister Jens Spahn warns of incidences beyond the 800 mark as early as this fall. In addition to masking and spacing, the issues surrounding vaccines against the various mutations and regular, reliable testing are returning to the front pages of the news pages.


26. July 2021 | 13:55 CET | by Carsten Mainitz

BioNTech, Cardiol Therapeutics, CureVac - What is next?

  • Biotechnology

Are you smiling or shaking your head? Both are easily understandable reactions that investors might have in light of the latest statements from the Deutsches Aktien Institut (DAI). The DAI calls for better conditions for IPOs of growth companies to prevent such companies from migrating to foreign stock exchanges, as happened with BioNTech, among others. "Especially companies with specialized business models and high financing needs are dependent on foreign investors," explained Uta-Bettina von Altenbockum. However, this is not a new phenomenon either. Other countries have been creating better framework conditions for corporations and better tax incentives for investors for a long time. Own goal. What opportunities are there?


23. July 2021 | 11:37 CET | by André Will-Laudien

CureVac, XPhyto Therapeutics, BioNTech, NanoRepro - Continuous testing or vaccination or both?

  • Biotechnology

Public confusion reigns. The pandemic seems to be locked in chains over the summer, and the population is happy about initial relief with incidences below 10. But now, the first vacationers are already coming back, partly from risk or mutation areas and have to go for testing again as vaccinated persons. It is often forgotten that even those who have been fully vaccinated can be carriers of the virus and can also fall ill, so it should be clear to everyone that personal protective measures must continue to be kept high. Our life with the COVID virus will last much longer than many want to believe...